Multiple Sclerosis Clinical Trial
Official title:
Examining the Impact of an Online, Non-restrictive Diet Among Persons With Multiple Sclerosis
Verified date | August 2023 |
Source | University of North Texas, Denton, TX |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current study aims to test an online, non-restrictive diet among persons with multiple sclerosis (MS). Diet is the number one searched second-line therapy among persons with MS, however there are currently no established dietary approaches to improve health and wellbeing among persons with MS. Participants will complete the 8-week diet program using an online application. The primary research question is whether the diet program is acceptable and can improve general health indicators including cholesterol, glucose, body weight, body fat as well as MS symptoms (i.e., walking, cognition, fatigue, and quality of life).
Status | Completed |
Enrollment | 16 |
Est. completion date | April 19, 2023 |
Est. primary completion date | April 19, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - age 18-70 years - a self-reported diagnosis of multiple sclerosis - relapse free in past 30 days - non-pregnant - willing and able to visit University of North Texas on two testing occasions Exclusion Criteria: - electronic medical implant, such as a heart pacemaker or an implantable cardioverter defibrillator (ICD) |
Country | Name | City | State |
---|---|---|---|
United States | University of North Texas | Denton | Texas |
Lead Sponsor | Collaborator |
---|---|
University of North Texas, Denton, TX |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Acceptability of Intervention | Participants ratings of satisfaction with the diet program. Scores range from 1-5 with higher scores indicating greater satisfaction. | From recruitment to end of 8 week intervention | |
Primary | Metabolic Health | Fasted Cholesterol and Gloucose | From recruitment to end of 8 week intervention | |
Primary | Body Weight | Change in Body Weight | From recruitment to end of 8 week intervention | |
Primary | Body Fat | Change in Body Fat Percentage | From recruitment to end of 8 week intervention | |
Secondary | 6-Minute Walk | Change in 6-Minute Walk Distance | From recruitment to end of 8 week intervention | |
Secondary | 25-Foot Walk | Change in 25-Foot Walk Speed | From recruitment to end of 8 week intervention | |
Secondary | Cognitive Assessments | Change in the Brief International Cognitive Assessment in MS Scores. Scores range from 0-208 with higher scores indicating greater cognitive functioning. | From recruitment to end of 8 week intervention | |
Secondary | Fatigue | Change in Fatigue Severity Scale Scores. Scores range from 1-7 with higher scores indicating greater fatigue. | From recruitment to end of 8 week intervention | |
Secondary | Health-Related Quality of Life | Change in SF-12 Scores. Scores range from 0-100 with higher scores indicating greater health-related quality of life. | From recruitment to end of 8 week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |